Commitments and Contingencies (Textual 3) - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified |
12 Months Ended | |
---|---|---|
Dec. 31, 2006
|
Dec. 31, 2004
|
|
Tasimelteon | ||
Payment to BMS as an initial license fee | $ 0.5 | |
Possible future tasimelton milestone payments to BMS | Less than $40.0 million | |
Milestone payment under license agreement | 1.0 | |
Future percentage of royalty payments based net sales of tasimelteon | Low teens | |
Percentage of future sublicense fees payable to BMS | Mid-twenties | |
License Agreement | Upon acceptance of NDA by FDA
|
||
Tasimelteon | ||
Obligation to make tasimelteon milestone payments | 3.0 | |
License Agreement | Upon approval of NDA by FDA
|
||
Tasimelteon | ||
Obligation to make tasimelteon milestone payments | $ 8.0 |